All In Biotech

Drug Trial Radar · NCT07187765

Respiratory Safety of Oliceridine During Sedated Gastrointestinal Endoscopy

Respiratory Safety of Oliceridine in Propofol-Sedated Gastrointestinal Endoscopy: A Double-Blind, Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 508 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

508

Actual

Start

Sep 22, 2025

Primary completion

Nov 30, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Shiyou WeiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, single-center, double-blind, randomized controlled trial designed to evaluate the effect of oliceridine versus sufentanil on the incidence of hypoxemia in adult patients undergoing gastrointestinal endoscopy under deep sedation. The trial will compare the rates of hypoxemia (defined as SpO₂ ≤92%) between the two analgesic regimens when combined with propofol. The primary aim is to determine whether oliceridine can reduce the incidence of hypoxemia compared to sufentanil during endoscopic procedures.

Conditions

  • Hypoxemia During Surgery
  • Gastrointestinal Endoscopy

Interventions

  • OliceridineDrug

    Oliceridine will be administered intravenously at a dose of 1 mg for gastroscopy or 1.5 mg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.

  • SufentanilDrug

    Sufentanil will be administered intravenously at a dose of 5 μg for gastroscopy or 7.5 μg for colonoscopy, in combination with propofol (1-2 mg/kg), to provide sedation and analgesia during gastrointestinal endoscopy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Hypoxemia (SpO₂ ≤92%) During Sedation for Gastrointestinal EndoscopyTime frame: From the start of sedation to the end of the gastrointestinal endoscopic procedure (approximately 1-60 minutes)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianmen First People's Hospital

    Tianmen, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.